Enhanced acquisition of reversal training in a spatial learning task in rats treated with chronic nimodipine.
Nimodipine levels were measured in blood and brain of rats implanted SC with sustained-release pellets of nimodipine (0, 10, 20, or 40 mg). Dose-dependent levels of nimodipine were detected in both plasma and brain. These results indicated the possible usefulness of these pellets in behavioral studies where long-term treatment is required. Therefore, the effects of chronic nimodipine, using 40-mg pellets, were examined on the performance of young, middle-aged, and aged rats in the Morris water maze. Following implantation of either nimodipine or placebo pellets, rats were trained for 6 days (three sessions/day) followed by 6 days of reversal training. During both initial and reversal training, every sixth trial was a probe trial. During initial training, there were clear age-related acquisition deficits in place training, with no effects of chronic nimodipine. Nimodipine did, however, enhance performance of rats during the first and second probe trials of reversal training. Time spent in the training quadrant by nimodipine-treated rats was approximately 30% longer on the first reversal probe and 35% longer on the second reversal probe than time spent in this quadrant by placebo-treated animals. These results indicate that chronic nimodipine enhances the performance of normal animals in reversal training on a spatial learning task.
McMonagle-Strucko
K
K
Institute for Preclinical Pharmacology, Miles Inc., West Haven, CT 06516.
Fanelli
R J
RJ
D000375:Aging / Q000523:psychology; D000818:Animals; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004343:Drug Implants; D008297:Male; D008568:Memory / Q000187:drug effects; D009553:Nimodipine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D012193:Reversal Learning / Q000187:drug effects*; D013028:Space Perception / Q000187:drug effects*; D013268:Stimulation, Chemical
D003692:Delayed-Action Preparations; D004343:Drug Implants; D009553:Nimodipine